4.8 Article

Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

Journal

NATURE MEDICINE
Volume -, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41591-023-02543

Keywords

-

Ask authors/readers for more resources

This study examined the feasibility of orally delivered senolytic therapy for Alzheimer's disease. The results showed that the treatment had a positive impact on the safety, tolerability, and feasibility of patients, and the drugs were able to penetrate the central nervous system. Biomarker data provided insights into the senolytic effects, but further research with larger sample sizes and placebo-controlled studies is needed for confirmation.
Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label, proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and quercetin (Q), was conducted in early-stage symptomatic patients with AD to assess central nervous system (CNS) penetrance, safety, feasibility and efficacy. Five participants (mean age = 76 + 5 years; 40% female) completed the 12-week pilot study. D and Q levels in blood increased in all participants (12.7-73.5 ng ml-1 for D and 3.29-26.3 ng ml-1 for Q). In cerebrospinal fluid (CSF), D levels were detected in four participants (80%) ranging from 0.281 to 0.536 ml-1 with a CSF to plasma ratio of 0.422-0.919%; Q was not detected. The treatment was well-tolerated, with no early discontinuation. Secondary cognitive and neuroimaging endpoints did not significantly differ from baseline to post-treatment further supporting a favorable safety profile. CSF levels of interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) increased (t(4) = 3.913, P = 0.008 and t(4) = 3.354, P = 0.028, respectively) with trending decreases in senescence-related cytokines and chemokines, and a trend toward higher A & beta;42 levels (t(4) = -2.338, P = 0.079). In summary, CNS penetrance of D was observed with outcomes supporting safety, tolerability and feasibility in patients with AD. Biomarker data provided mechanistic insights of senolytic effects that need to be confirmed in fully powered, placebo-controlled studies. ClinicalTrials.gov identifier: NCT04063124. The first feasibility study of orally delivered senolytic therapy in Alzheimer's disease reports favorable safety data and penetrance of dasatinib into the brain with a modest impact on Alzheimer's and aging biomarkers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available